LP is an organizational structure and a set of rules for conducting
research studies to be submitted to regulatory bodies such as the FDA,
EPA, and comparable agencies in Europe. As such, the rules are vague
enough to be unhelpful in conducting research, but detailed enough to
create a burden on the investigator. Their purpose is to enable every
aspect of a study to be reconstructed by a third party. This book
describes the rules in narrative format, then provides the actual
rules from the OCED, FDA, and EPA in an appendix.
If you're interested in bureaucratic regulations for some reason, or if you are forced to learn about GLP, this book is a good way to do it. The subject matter is intrinsically boring, but the writing style is reasonably good. Do not buy this book yourself: your employer should be paying you to read this crap -- er, stuff.
gentle introduction to the pharmaceutical industry as of 2008.
Written at an undergraduate level with lots of extra useless words.
Informal writing style. A good way for beginning pharmacology
students or technicians to learn about the drug industry. Not
really useful for chemists as the title implies, unless by
"chemists" you mean students and associates.
his book is a general review of the technology
and principles for creating biosensors. oriented toward analytical chemists
wishing to expand into detection of biomolecules. It discusses amperometric
detectors, field effect sensors, potentiometric sensors, light addressable
potentiometric sensors, fiber optic devices, evanescent wave, surface plasmon
resonance, electrogenerated chemiluminescence, thermal sensors, and acoustic
wave devices. Doesn't give the level of detail as the excellent Bioconjugate
Techniques, which gives a wealth of information on covalent modification
of proteins, and doesn't discuss procedures for actually building or using
the biosensors like Affinity Biosensors: Techniques and Protocols,
but has numerous literature references for those who need more detailed
and specific information, and is mainly useful as a source of ideas.
his book consists mainly of a collection of tabulated data of food
and water contaminants in 36 American cities. This is an important
topic. Unfortunately, the data
are woefully incomplete. Most of the numbers are not pollutant levels,
but totals of the number of times a particular chemical was detected.
But what method was used? What was the sensitivity level? Today's
ultrasensitive equipment can measure vanishingly small levels of
contaminants. What concentration was actually measured? What was
the variability? Without this information, to say that something was
"detected" is to say almost nothing at all. Any conclusions drawn from
such data would be equally suspect.
Many of the numbers that do represent real quantities are also not credible. For example, Table 8-7 shows New York City with a total of 7 pounds of toxic air pollutants released between 1996 and 2001, while Baton Rouge had 32,051,286 pounds. Does this make any sense? Appendix 8, which lists toxic air pollutants by city, lists the concentrations of 42 substances for Charleston, SC, but only two substances for Binghamton, NY. Only once--in a graph showing the acrylamide concentrations in various brands of potato chips (p. 197)--is any number in the book accompanied by an estimate of error. The authors say that hot dogs and tuna are contaminated with chloroform. What hotdogs and tuna? How much chloroform? One part per billion? Ten thousand? How is anyone supposed to use data like this?
The authors say (p.13) that knowledge of chemistry is not needed to understand the toxicological implications of the data. That is true, if all you want to do is frighten uninformed people. If, on the other hand, you want to find out whether a given pollutant is a problem, you need to know a great deal of chemistry. And if, for some inscrutable reason, you wanted to know what's really happening in the environment, you would need some real numbers, and some meaningful ones. Maybe someday we will get them.
n this short, non-technical book, John LaMattina, the former president of
Pfizer Global Research and Development, provides an articulate defense
of the pharmaceutical industry. Says LaMattina: “Only pharmaceutical
R&D discovers, develops, manufactures, tests, and demonstrates the properties
of compounds that prove or disprove medical hypotheses.” LaMattina
describes the stories of successful and unsuccessful drugs, including
torcetrapib, a heart disease drug that Pfizer spent 15 years and 800
million dollars on, only to have it fail in Phase 3 testing. A fascinating
memoir by an impressive scientist.